我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

缬沙坦治疗轻、中度高血压病的疗效和安全性 (PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2004年第2期
页码:
149-151,155
栏目:
临床研究
出版日期:
2004-03-01

文章信息/Info

Title:
Efficacy ands afety of Valsartanin the treatment of mild to moderate essential hypertension
作者:
翁南星1; 吴奇志2; 郑东阳1
1.厦门市杏林医院内科; 2.厦门市湖里医院,福建 厦门 361022
Author(s):
WENG Nan-xing 1;  WU Qi-zhi 2;  ZHENG Dong-yang 1
1.Department of Cardiology,Xiamen XingLin Hospital, Xiamen, Fujian 361022, China
关键词:
高血压;  缬沙坦;  依那普利
Keywords:
hypertension;  Valsartan;  Enalapr
分类号:
R541.3
DOI:
-
文献标识码:
A
摘要:
目的:评价缬沙坦(Valsartan,VAL)治疗轻、中度高血压病的疗效和安全性。方法:采用随机、单盲和平行对照方法,经1周药物冲洗期及2周安慰剂导入期后,102例轻、中度高血压患者进入8周治疗期,每日1次服用VAL80mg(52例)或依那普利(Enalapril,ENA)5mg(50例),2周后如坐位舒张压(SiDBP)≥90mm Hg(1mm Hg=0.133kPa)则剂量加倍,4周后如仍无效则每日加服双氢克尿噻25mg。于服安慰剂期末及治疗2、4、6、8周末测诊室血压,心率(HR)并记录症状、体征;于服安慰剂末及治疗8周末行24h动态血压监测(ABPM)各1次。结果:两组药物均能明显降低血压(P<0.01);VAL组有效率92%,ENA组有效率88%,组间比较无显著性差异(P>0.05)。8周末VAL组SiSBP/SiDBP下降(21±9)/(16±5)mmHg,ENA组下降(20±9)/(13±7)mmHg。2、4、6、8周末血压下降值,组间比较无显著性差异(P>0.05)。VAL组和ENA组分别有44%和60%患者加用利尿剂。VAL降压谷峰值比率69%,ENA为49%。咳嗽发生率VAL组(4%)明显低于ENA组(18%),差异有显著性(P<0.05)。结论:VAL(80～160mg/d)对轻、中度高血压病疗效确切、安全、耐受性好,干咳的不良反应明显低于血管紧张毒素转换酶抑制剂(ACEI)。
Abstract:
AIM: To evaluate the efficacy and safety of Valsartan (VAL) in the treatmen to fmild Tomoderate essential hypertension. METHODS: A randomized, single-blind and parallel study Was peformed. Aftera 1-week wash out and 2-week place boren-in period, 102 patient sentered an 8-week randomized, parallel study with either 80 mg VAL (n=52) or 5 mg Enalapri l(ENAn= 50) once daily. Adouble dose of VAL or ENA and thead dition of dihydro chlorothiazide 25 mg Once daily were required if the patients' diastolic blood pressures (SiDBP) were equal to or higher Than 90 mmHg (1mmHg=0.133kPa). At the end of place borun-in and 2、4、6、8 weeks after The treatment, the result of clinical blood pressure, heartrate (HR), symptom sand signs were recorded; at the end of place borun-in and 8-week aftert he treat ment, blood pressure was monitored (ABPM). RESULTS: At the end of 8 weeks, no statistical difference was found between the effective rates of VAL and ENA (92.0% vs88.0%,P> 0.05). SiSBP/SiDBP decreased by (21±9)/(16±5) mmHg by VAL and(20±7)/(13±7 )mmHg by ENA. There was no difference in the decrease in blood pressure between the two groups at the end of 2,4,6 and 8 weeks (P>0.05). Placebo-corrected trough: peak ratio were 69% by VAL and 49% by ENA. The prevalence of cough was significantly lower in the VAL group than in the ENA group (3.8% Vs 18.0%, respectively, P<0.01). CONCLUSION: VAL 80～160 mg once daily is effective, Safe and well tolerated in mild to mode rate essential hypertension patients without the sid effect Of cough.

参考文献/References

[1]Criscione L,Gasparo M,Buhlmayer P,et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonistoftheangiotensinⅡ AT1-receptor subtype[J]. Br J Pharmacol,1993,110:761-771.

[2]JiH,Leung M,Zhang Y,etal. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotens in receptor: identification of amino acid residues the determine binding of the antihypertensive drug losartan[J]. J Biol Chem,1994,269:16533-16536.

[3]Data on file.Integrated Summary of Safety for Valsarten[C].Ciba-Geigy corporation. Summit, USA,1995.

[4]Thurmann P. AngiotensinⅡ antagonism and the heart:valsartanin left ventricular hypertrophy. Novel approaches in treationghy pertension and renal disease via blockade of renin angion tensin system. Satellite Symposium of the European Society of Hypertension-8th[C]. European Meeting on Hypertension,1997,Milan,ltaly.

[5]Multicentre, randomized, double-blind, placebo-controlled, between patient trial to determine the tolerability and effect ofvalsartan 80 mg once daily on renal function in hypertensive patients with stable renal in sufficiency treated for 6 months. Protocol 26[C]. Ciba-Gdigy Limited, Basel Switzerland,1996.

[6]朱理敏,王宪衍.抗高血压药物降压作用谷/峰比的作用与探讨[J],新药与临床,1996,15:236-238.

[7] Morgan J, Harb G, Byraw, etal. Effect of plasma concentration of angiotensin-Ⅱ antagonist, valsartan on the pressor response to angiotensin-Ⅱ in healthy males (Abstr) [J]. J Clin Pharmacol, 1995,35:930.

[8]Holwerda NJ,Fogari R,Angeli P,et al.Valsartan, a new angiotensin-Ⅱ antagonist for the treatment of essential hypertensin: efficacy and safety compared with place boand enalapril[J]. J Hypertens, 1996,14:1147-1151.

[9]A double-blind,randomized,active-controlled,parallel design trial comparing the efficacy of the combination of hydrochlorothiazide 12.5 mg or 25 mg plus valsartan 80 mg once daily to valsartan 160 mg once daily in hypertensive patients in adequately controlled with valsartan 80 mg once daily[C].Dataonfile.Protocol19.Ciba-Geigy Cor poration,1995.

[10]Mancia G,Frattola A,Groppelli A,et al.Blood pressure reduction and end-organ damage in hypertension[J]. J Hypertens, 1994,12(Sunpl8):S35-S42.

[11]Tsementzis SH,Gill TS,Hitchcock ER, e tal. Diurnal variation of and activity during the onset of stroke[J]. Neurosurgery,1985,17:901-904.

[12] Lacourciere Y. Lefebvre J. Modulation of the renin angio tensin-aldoster one syste mand cough[J].Can J Cardiol,1995,11(SupplF):33F-39F.

[13]Tikkanen I,Omvik P,JensenH AE,et al.Comparison of the angiotensinⅡ antagonist losartan with the angion tensinⅡ antagonistlosartan with the angio tensin converting enzyme inhibitor enalaprilin patients with essential hypertension[J]. Hypertension, 1995,13:1343-1351.

备注/Memo

备注/Memo:
收稿日期：2003-3-3
更新日期/Last Update: 2004-03-01